Abstract
(Reprinted with permission from The American Journal of Psychiatry 2019; 176:401–409)
Keywords: Mood Disorders-Unipolar, Clinical Drug Studies, Ketamine, Treatment-Resistant Depression
. 2020 Apr 23;18(2):236–243. doi: 10.1176/appi.focus.18206
Single, Repeated, and Maintenance Ketamine Infusions for Treatment-Resistant Depression: A Randomized Controlled Trial
Jennifer L Phillips
1,✉, Sandhaya Norris
1, Jeanne Talbot
1, Meagan Birmingham
1, Taylor Hatchard
1, Abigail Ortiz
1, Olabisi Owoeye
1, Lisa A Batten
1, Pierre Blier
1
Jennifer L Phillips, Ph.D.
1From the Mood Disorders Research Unit, The Royal’s Institute of Mental Health Research, Ottawa (Phillips, Norris, Talbot, Birmingham, Hatchard, Ortiz, Owoeye, Batten, Blier); the Department of Psychiatry, University of Ottawa (Phillips, Norris, Talbot, Owoeye, Blier); and the Department of Cellular and Molecular Medicine, University of Ottawa (Blier).
Find articles by Jennifer L Phillips
Sandhaya Norris, M.D.
1From the Mood Disorders Research Unit, The Royal’s Institute of Mental Health Research, Ottawa (Phillips, Norris, Talbot, Birmingham, Hatchard, Ortiz, Owoeye, Batten, Blier); the Department of Psychiatry, University of Ottawa (Phillips, Norris, Talbot, Owoeye, Blier); and the Department of Cellular and Molecular Medicine, University of Ottawa (Blier).
Find articles by Sandhaya Norris
Jeanne Talbot, M.D., Ph.D.
1From the Mood Disorders Research Unit, The Royal’s Institute of Mental Health Research, Ottawa (Phillips, Norris, Talbot, Birmingham, Hatchard, Ortiz, Owoeye, Batten, Blier); the Department of Psychiatry, University of Ottawa (Phillips, Norris, Talbot, Owoeye, Blier); and the Department of Cellular and Molecular Medicine, University of Ottawa (Blier).
Find articles by Jeanne Talbot
Meagan Birmingham, M.A., M.B.A.
1From the Mood Disorders Research Unit, The Royal’s Institute of Mental Health Research, Ottawa (Phillips, Norris, Talbot, Birmingham, Hatchard, Ortiz, Owoeye, Batten, Blier); the Department of Psychiatry, University of Ottawa (Phillips, Norris, Talbot, Owoeye, Blier); and the Department of Cellular and Molecular Medicine, University of Ottawa (Blier).
Find articles by Meagan Birmingham
Taylor Hatchard, Ph.D.
1From the Mood Disorders Research Unit, The Royal’s Institute of Mental Health Research, Ottawa (Phillips, Norris, Talbot, Birmingham, Hatchard, Ortiz, Owoeye, Batten, Blier); the Department of Psychiatry, University of Ottawa (Phillips, Norris, Talbot, Owoeye, Blier); and the Department of Cellular and Molecular Medicine, University of Ottawa (Blier).
Find articles by Taylor Hatchard
Abigail Ortiz, M.D.
1From the Mood Disorders Research Unit, The Royal’s Institute of Mental Health Research, Ottawa (Phillips, Norris, Talbot, Birmingham, Hatchard, Ortiz, Owoeye, Batten, Blier); the Department of Psychiatry, University of Ottawa (Phillips, Norris, Talbot, Owoeye, Blier); and the Department of Cellular and Molecular Medicine, University of Ottawa (Blier).
Find articles by Abigail Ortiz
Olabisi Owoeye, M.D.
1From the Mood Disorders Research Unit, The Royal’s Institute of Mental Health Research, Ottawa (Phillips, Norris, Talbot, Birmingham, Hatchard, Ortiz, Owoeye, Batten, Blier); the Department of Psychiatry, University of Ottawa (Phillips, Norris, Talbot, Owoeye, Blier); and the Department of Cellular and Molecular Medicine, University of Ottawa (Blier).
Find articles by Olabisi Owoeye
Lisa A Batten, Ph.D.
1From the Mood Disorders Research Unit, The Royal’s Institute of Mental Health Research, Ottawa (Phillips, Norris, Talbot, Birmingham, Hatchard, Ortiz, Owoeye, Batten, Blier); the Department of Psychiatry, University of Ottawa (Phillips, Norris, Talbot, Owoeye, Blier); and the Department of Cellular and Molecular Medicine, University of Ottawa (Blier).
Find articles by Lisa A Batten
Pierre Blier, M.D., Ph.D.
1From the Mood Disorders Research Unit, The Royal’s Institute of Mental Health Research, Ottawa (Phillips, Norris, Talbot, Birmingham, Hatchard, Ortiz, Owoeye, Batten, Blier); the Department of Psychiatry, University of Ottawa (Phillips, Norris, Talbot, Owoeye, Blier); and the Department of Cellular and Molecular Medicine, University of Ottawa (Blier).
Find articles by Pierre Blier
1From the Mood Disorders Research Unit, The Royal’s Institute of Mental Health Research, Ottawa (Phillips, Norris, Talbot, Birmingham, Hatchard, Ortiz, Owoeye, Batten, Blier); the Department of Psychiatry, University of Ottawa (Phillips, Norris, Talbot, Owoeye, Blier); and the Department of Cellular and Molecular Medicine, University of Ottawa (Blier).
Presented in part at the International College of Neuropsychopharmacology Thematic Meeting, Prague, July 20–21, 2017; the 67th Canadian Psychiatric Association Annual Conference, Ottawa, September 14–16, 2017; the 56th Annual Meeting of the American College of Neuropsychopharmacology, Palm Springs, Calif., December 3–7, 2017; the Society of Biological Psychiatry 73rd Annual Scientific Convention and Program, New York, May 10–12, 2018; and the 31st International College of Neuropsychopharmacology World Congress, Vienna, June 16–19, 2018.
✉
Send correspondence to Dr. Phillips (Jennifer.Phillips@theroyal.ca).
✉
Corresponding author.
Received 2018 Jul 16; Revised 2018 Oct 12; Accepted 2018 Nov 19; Issue date 2020 Apr.
Copyright © 2020 by the American Psychiatric Association
PMCID: PMC7587876 PMID: 33343241